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Autoimmune hepatitis in patients with human
immunodeficiency virus infection
A systematic review of the published literature
Mohamad Mubder, MDa,
∗
, Mohamed Azab, MDb, Mahendran Jayaraj, MDe, Chad Cross, PhDc,
Daisy Lankarani, MDe, Banreet Dhindsa, MDa, Jen-Jung Pan, MD, PhDd, Gordon Ohning, MD, PhDe
Abstract
Background: Liver disease in patients with HIV is common and typically has complex and multifactorial presentations that
represent a major cause of morbidity and mortality. Autoimmune hepatitis (AIH) is rarely reported in patient with HIV and the disease
course and clinical outcomes for treatment have not been well characterized. We are aiming to determine the patient characteristics,
disease prevalence, and treatment outcomes from published articles of patients with HIV and AIH.
Method: A systematic search of PubMed, Web of Science, and Google Scholar through February 20th, 2019 identified 15 studies
that reported the outcomes of AIH in patients with HIV. Because of the small sample sizes and skewed distributions, resampling tests
of mean differences using permutation distributions (MAXn=10,000 permutations) were utilized; analyses were performed using R (v.
3.5.1). Categorical differences were calculated using Fisher exact test for odds ratio = 1 (equal odds), and Cramer V was calculated
for effect size; analyses were completed in SPSS (v. 25).
Results: By reviewing 15 studies reporting a total of 35 patients with AIH and HIV, male patients were found to have significantly
higher aspartate transaminase and alanine transaminase levels at time of diagnosis. No other significant findings identified. The CD4
count and viral load did not show significant correlation with AIH diagnosis or its prognosis. All patients but one who presented with
severe immune deficiency and responded to highly active anti-retroviral therapy received immunosuppressive treatment without side
effects and achieved remission except 2 lost to follow-up and 3 expired.
Conclusion: Although rare, but AIH can develop in patients with HIV and physicians should consider it in the differential diagnosis
for HIV patients presented with abnormal liver function tests, especially after excluding hepatitis C virus and drug-induced liver injury.
Patients with immune deficiency disorders who present with AIH can be treated safely with steroid either as monotherapy or in
combination with another immune suppressant therapy.
Abbreviations: AIH = autoimmune hepatitis, ALT = alanine transaminase, ANA = antinuclear antibodies, anti-LC1 = anti-liver
cytosol type 1, anti-LKM1 = anti-liver/kidney microsome type 1, ASMA = anti-smooth muscles antibodies, AST = aspartate
transaminase, HAART = highly active anti-retroviral therapy, HIV = Human immune deficiency virus.
Keywords: autoimmune hepatitis, HIV infection
1. Introduction
Autoimmune hepatitis (AIH) is a chronic inflammatory liver
disease characterized by the presence of circulating autoanti-
bodies such as anti-nuclear antibodies (ANA), anti-smooth
muscles antibodies (ASMA), anti-liver/kidney microsome type 1
(anti-LKM1), or anti-liver cytosol type 1 (anti-LC1) with
hypergammaglobulinemia and typical histological changes like
interface hepatitis, plasmacytic infiltrates, and regenerative liver
cell rosettes.[1–3] AIH can present at any age, ethnic group, or sex
with a female predominance.[4,6] The exact etiology is unknown
but proposed to be caused by an environmental trigger associated
with defective immune tolerance mechanism in a genetically
predisposed individual. This elicits a T-cell-mediated immune
reaction targeting hepatocytes leading to progressive inflamma-
tion and injury that can end with liver cirrhosis.[4,5] AIH has a
variety of clinical phenotypes; therefore, it is included in the
differential diagnosis for patients with abnormal liver biochemi-
cal tests, acute hepatitis, cirrhosis, or acute liver failure.[7] It may
present as either an acute or chronic disease with a fluctuating
pattern.[8,9] However, the spectrum of presentation also includes
asymptomatic patients.
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Since the first description of human immunodeficiency virus
(HIV) in 1981, there have beenmultiple advances in the diagnosis
and management of the disease, which have directly affected its
prevalence and prognosis. In the anti-retrovirus therapy era for
HIV infection, liver diseases are considered one of the most
common causes of non–AIDS-related mortality in this population
with HIV. This is most commonly as a result of chronic hepatitis
B virus (HBV) or hepatitis C virus (HCV) co-infection,
medication-related hepatotoxicity, alcohol abuse, or nonalco-
holic fatty liver.[3,17] According to the Centers for Disease
Control and Prevention (CDC), there have been 1.1 million
adults aged 13 years and above living with HIV in the United
States with 38,500 estimated new cases annually.[10]
Chronic infection with HIV is characterized by a steady decline
in CD4+T-cell count in proportion to the viral burden resulting in
a progressive waning of humoral immunity. This also leads to
stimulation of B-Cell proliferation and increased immunoglobu-
lins’ production a proportion of which may be defective. This
immunological dysregulation greatly increases the risk for the
development of autoimmune diseases like AIH.[11,12]
Herewith we are providing a systematic review of the available
literature on this topic of AIH in HIV patients. With this review,
we aim to characterize this population, discuss the patterns by
which AIH and HIV affect one another in terms of severity,
prognosis, and treatment.
2. Method
We performed a systematic review of available literature on
PubMed, Web of Science, and Google Scholar using the words
“autoimmune hepatitis in human immune deficiency virus,”
“AIH in HIV,” “Autoimmune diseases in HIV” to extract
published articles from January 1st 2000 up to February 20th,
2019 identifying 15 literatures that reported the outcomes of AIH
in a total of 35 patients with HIV. Only studies with a liver
biopsy-confirmed diagnosis were included in concordance with
the AIH group revised criteria. All studies included were written
in English except one that was translated from French using
Google translate.
An institutional review board approval was not necessary as
this study is systematic review of literature and meta-analysis.
Most studies resulted in very limited information, with several
single-case reports. Therefore, it was not possible to develop a
traditional meta-analytic approach to combining results, and
data were combined using sample-size weights for analyses.
Because of the small sample sizes and skewed distributions,
resampling tests of mean differences using permutation distri-
butions (MAXn=10,000 permutations) were utilized; these
analyses were performed using R (v. 3.5.1). Categorical differ-
ences were calculated using Fisher exact test for odds ratio = 1
(equal odds), and Cramer V was calculated for effect size; these
analyses were completed in SPSS (v. 25; SPSS Inc, Chicago, IL).
3. Results
Fifteen articles reporting a total of 35 patients with AIH and HIV
were included (Table 1). Twenty-six (74.2%) were females and 9
(25.8%) were males with a mean age of 45.7 years and 38.5
years, respectively.
The mean CD4 count at time of diagnosis was 534.85cells/
mm3 for females and 533.78cells/mm3 for males and most cases
developed AIH with undetectable HIV viral load except 7 cases
had elevated viral loadwithmean of 61,693copies/mL at the time
of diagnosis and 2 cases with unreported viral load. HCV
coinfection was reported in 5 cases (14.2%) andHBV coinfection
in 2 cases (5.7%) (Table 2). Other autoimmune diseases coexisted
in 6 patients (17.1%) with vitiligo in 1 case, lupus in 2 cases, and
Graves disease in 2 cases and 1 case with myasthenia gravis.
Males had significantly higher alanine aminotransferase (ALT;
751.89U/L vs 181.04U/L, P= .035) and aspartate aminotrans-
ferase (AST; 751.89U/L vs 198.16U/L, P= .037) than females.
Both sexes have similar alkaline phosphatase levels (Table 2).
Liver biopsywas performed to confirm the diagnosis of AIH in all
patients using the revised criteria of the International Autoimmune
Hepatitis group (IAH+IHG) score of >15[3,13] (Table 3).
All patients were on highly active anti-retroviral therapy
(HAART) therapy at time of diagnosis with 15 patients (42.8%)
receiving efavirenz, emtricitabine, and tenofovir and 4 patients on
unknown regimen at the time of diagnosis.
Table 1
List of included literature.
Author Date of study Number of patients
Kia et al[1] 2017 5
Zoboli et al[2] 2017 2
Parekh et al[3] 2017 2
German[5] 2004 1
Puius et al[19] 2006 3
Vispo et al.[20] 2008 1
Caplan[21] 2013 1
O’Leary et al[25] 2008 1
Daas et al[26] 2011 1
Murunga et al[27] 2014 9
Cazanave et al[28] 2005 1
Wan et al[29] 2009 4
Ofori et al[30] 2017 2
Hagel et al[31] 2012 1
Coriat et al[32] 2008 1
Table 2
Summary of the results.
Continuous variables
Sex n Mean SD P
Age Female 21 45.71 10.91 .129
Male 8 38.50 11.26
CD4 Count at Dx Female 26 534.85 286.18 .992
Male 9 533.78 247.57
AST Female 25 198.16 300.20 .037
Male 9 751.89 1209.87
ALT Female 26 181.04 307.27 .035
Male 8 853.22 1549.79
ALP Female 26 81.87 140.90 .916
Male 8 75.45 80.90
Period of follow-up Female 20 8.18 12.49 .653
Male 7 10.79 8.62
Categorical variables
Sex No (%) Yes (%) Cramer V P
HCV coinfection Female 19 (82.6) 4 (17.4) 0.035 >.999
Male 6 (85.7) 1 (14.3)
HBV coinfection Female 23 (100.0) 0 (0.0) 0.445 .060
Male 6 (75.0) 2 (25.0)
ALP= alkaline phosphatase, ALT= alanine transaminase, AST= aspartate transaminase, HBV=
hepatitis B virus, HCV=hepatitis C virus.
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All cases were treated successfully with immunosuppressants
including steroid as monotherapy or tapered steroid with
addition of other immunosuppressive (azathioprine). Two cases
were exception as 1 case presented with severe immune deficiency
and responded to HAART and 1 case refused treatment. Thirty
patients had complete remission, 2 cases lost to follow–up, and 3
patients died (1 patient because of fulminant liver failure, 1
because of CMV viremia, and 1 because of Burkitt lymphoma).
The range of follow-up was 1 to 48 months with an average of
9.48 months (Table 2).
4. Discussion
AIH is a rare entity of liver disease with specific serological and
histological findings characterized by insidious onset of immu-
nological reaction against hepatocytes causing progressive
inflammation and fibrosis leading to liver cirrhosis.[5] Interna-
tional Autoimmune Hepatitis Group scoring system that was
developed originally in 1999 has been beneficial in diagnosing
this condition and amore simplified version of this scoring system
has been adopted in 2008 incorporating laboratory results and
histological findings on liver biopsy (Table 3).[3,13] Treatment
usually includes high-dose steroids as monotherapy or low-dose
steroids in combination with immunosuppressants (eg, azathio-
prine). AIH in patients with established HIV infection has been
rarely reported in the literature and the disease course, prognosis,
and response to therapy have not been well documented.[5]
Elevated liver enzymes in patients infected with HIV are
usually related to viral hepatitis, alcoholic liver disease, drug-
induced toxicity, metabolic abnormalities, immune-mediated
cholestatic disease, or hereditary disorders. Given the nature of
HIV infection and its effect on the immune system, autoimmune
diseases have been infrequently described in such patient
populations and even less are cases describing HIV patients
with diagnosis of AIH, which can have significant consequences
on its management and prognosis.[2]
Initiation of HAART in HIV or AIDS patients with low CD-4
count has been associated with exacerbation of preexisting
immunological conditions such as sarcoidosis and thyroiditis as
part of systemic inflammatory response syndrome (SIRS). AIH
has been reported as a possible result of SIRS [22]; however, most
of the patients in our study were already on HAART with well-
controlled HIV at time of diagnosis of AIH.
Full evaluation of suspected cases of AIH in HIV patients starts
with a detailed history, evaluation of medication regimen, alcohol
consumption, and sexual history. It should also include
evaluation of conventional serological markers and liver biopsy
for histological evaluation.[4,13]
Initial laboratory evaluation of suspected cases includes ANA,
ASMA, anti-LKM1, and anti-LC1. Liver biopsy is recommended
early for diagnosis. Typical findings include prominent interface
with zone 1 hepatitis or irregularly distributed and relatively intense
portal infiltrate with either periportal or paraseptal interface
hepatitis. Other histopathological findings can be evaluated but are
usually less specific and less pathognomic. Based on serological
findings, AIH is usually classified into 2 types. Type I is
characterized by presence of ANA and ASMA and constitutes
80% of AIH cases. Type II is characterized with presence of anti-
LKM1 and anti-LC1 and is mostly found in children.[1–4,14,15]
The decision to start treatment for patients with AIH in general
depends on the severity of the clinical presentation (Table 4).[4] It
includes starting high-dose corticosteroid as a single agent or low-
dose steroids in conjunction with other immunosuppressants,
such as azathioprine. Later regimen can be tapered down
Table 3
Simplified criteria of international autoimmune hepatitis group 2008.
Points
Autoantibodies ANA, SMA, OR LKM >1: 40 1
ANA, SMA, OR LKM >1: 80 SLA/LP-positive (>20 U) 2
Ig G Upper limit of normal 1
>1.10 the upper limit of normal 2
Liver histology Compatible with AIH Chronic hepatitis with lymphocytic infiltrations without features considered typical 1
Typical for AIH interface hepatitis; lymphocytic/lymphoplasmacytic infiltrates in the portal tracts Emperipolesis:
active penetrations by one cell into and through larger cell hepatic rosette formation
2
Absence of viral hepatitis No 0
Yes 2
Interpretation Points >6: probable AIH Points >7: definite AIH
AIH= autoimmune hepatitis, ANA=anti-nuclear antibodies, ASMA= anti-smooth muscles antibodies, anti-LKM1= anti-liver/kidney microsome type 1, SLA/LP=Soluble liver antigen/liver-pancreas.
Table 4
Indication to start treatment in patient with AIH.
Absolute Relative none
• Serum AST >10-fold ULN • Symptoms (fatigue, arthralgia, jaundice) • Asymptomatic with normal or near normal
serum AST and gamma globulin levels
• Serum AST >5-fold ULN and
gamma globulin level >2-fold ULN
• Serum AST and/or c globulin less than absolute criteria • Inactive cirrhosis or mild portal inflammation
(portal hepatitis)
• Incapacitating symptoms • Interface hepatitis • Severe cytopenia
• Osteopenia, emotional instability, hypertension, diabetes, or cytopenia
(white blood cell counts <2.5109 cells/L or platelet counts <50109 cells/L)
• Vertebral compression, psychosis, brittle
diabetes, uncontrolled hypertension, known
intolerances to prednisone or azathioprine
AST= aspartate transaminase, ULN=upper limit of normal.
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individually to sustain enough suppression. The immunosup-
pressive dosage appears to be individualized to each patient as
different doses of azathioprine were used to achieve sustained
immunosuppression ranging from 50mg daily to 200mg daily.
Although it is controversial to start patients with chronic HIV
on immunosuppressive therapy given the risk of opportunistic
infection, worsening of HIV status, or increasing risk of
development of malignancies as shown by previous studies that
reported increase in Kaposi sarcoma in HIV patients on
immunosuppressive drugs,[16,15] it is still recommended to start
immunosuppressive treatment to achieve remission and prevent
disease progression.[2,3,19,20]
Particular attention is needed to evaluate for possible drug–
drug interaction between immunosuppressive medications like
azathioprine and antiretroviral medications, as they share
common elimination and metabolism pathways such as cyto-
chrome P450 enzyme system or P-Glycoprotein and MRP
pathways. These interactions are especially profound with
protease inhibitors. Studies done in patients with HIV who are
organ transplant recipients showed better drug–drug interaction
profile with integrase strand transferase inhibitors.
Our literature of interest did not report a specific interaction
associated with the use of maintenance immunosuppressive
medications like azathioprine and the HAART regimen.
Some studies mentioned the possibility of triggering AIH by HIV
infection or during the immune reconstitution phase after starting
the antiretroviral medications and correlated the development of
autoimmune diseases to high CD4 count, but no significant
correlation was demonstrated with subsequent studies.[1,5,18,23,24]
Our literature review did not show significance in a correlation
ofCD4count andHIVviral load indiagnosingAIHoranticipating
the severity of illness. AIH is more prevalent in the female
population that is aligned with the literature. AST and ALT levels
were significantly higher at time of diagnosis inmales compared to
females. Theoretically, this finding can be explained by hormonal
differences or difference in genetic expression. Also, it can be
explained by the presence of undiagnosed chronic hepatitis
conditions or were incorrect diagnosis with AIH, as drug-induced
liver injury can sometimes mimic AIH. Further studies are needed
to determine the sex differences in transaminases. Our review
supports the current recommendations of treating AIH in patients
with HIV with steroids as monotherapy or in conjunction with
other immunosuppressants mainly azathioprine.[4]
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